Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study
Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study
About this item
Full title
Author / Creator
Publisher
United States: Wolters Kluwer
Journal title
Language
English
Formats
Publication information
Publisher
United States: Wolters Kluwer
Subjects
More information
Scope and Contents
Contents
The objective was to assess the efficacy and safety of GED-0301, an antisense oligodeoxynucleotide to Smad7, in active Crohn's disease (CD).
This phase 3, blinded study randomized patients (1:1:1:1) to placebo or 1 of 3 once-daily oral GED-0301 regimens: 160 mg for 12 weeks followed by 40 mg continuously or alternating placebo with 40 or 160 mg...
Alternative Titles
Full title
Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2459360185
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2459360185
Other Identifiers
ISSN
0002-9270
E-ISSN
1572-0241
DOI
10.14309/ajg.0000000000000493
